Contact Us | News | Site Map
Aridis Pharmaceuticals © 2010 Le3 Web Designs
Technology Strategic Approach
Our strategic approach is to apply advanced formulation and delivery technologies to improve the effectiveness and deliver ability of our proprietary products, while at the same time leverage these technologies to solve our partners’ formulation challenges.
AerucinTM will be produced as refrigerator stable liquid formulation ready for parenteral injection for the pneumonia indication. PanaecinTM and will be produced as inhalable aerosols (nebulized liquid or inhalable dry powder) for deep lung delivery.
Our technology portfolio has garnered eight different government grants and research collaboration funding totaling more than seven million dollars, and comprise of formulation stabilization technology and delivery technologies in the form of inhalable powders for lung delivery and quick dissolving thin film for oral delivery of vaccines.
• Stabilization of Biopharmaceuticals